Wilson Sonsini Goodrich & Rosati advised Fluent Biosciences on the transaction. Illumina, Inc. (NASDAQ: ILMN) announced it has acquired Fluent BioSciences (Fluent), developer of an emerging...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Bakkt Holdings, Inc. on the transaction, and Goodwin Procter advised the placement agent. Bakkt Holdings, Inc. (Bakkt) (NYSE: BKKT), a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. United Therapeutics (Nasdaq:UTHR) announced it acquisition of all of the outstanding equity of IVIVA Medical, Inc., a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Nature’s Toolbox on the transaction. Nature’s Toolbox (NTx) announced the close of a $47.5 million Series B funding round led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Neuvivo in the deal. Neuvivo announced that it has closed an $11 million round of financing led by PrimeStreet Capital. The funding will...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Spring Lane Capital on the deal. Spring Free EV, a financial technology company accelerating the adoption of electric vehicles (EVs)...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction. Neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Think Bioscience on the deal. Think Bioscience, a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, announced it has...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised VitroLabs on the deal. VitroLabs Inc, a Bay-Area-based biotech company leading the development of a new scientific process to grow the world’s first...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
You must be a Standard 1 Year member to access this content.
